Table 2.
Effects of mutations on caffeine activation of RyR2
| Mutation | Apparent EC50 (mM) | Adjusted p value | N |
|---|---|---|---|
| A. Disease-associated mutations | |||
| RyR2 WT | 0.20 ± 0.03 | 5 | |
| P4902S | 0.14 ± 0.02 | 0.001 | 5 |
| P4902L | 0.10 ± 0.01 | <0.0001 | 5 |
| E4950K | 0.11 ± 0.01 | <0.0001 | 5 |
| G4955E | 0.05 ± 0.01 | <0.0001 | 5 |
| ANOVA summary: F = 40.7, p < 0.0001 | |||
| C. Other mutations | |||
| RyR2 WT | 0.20 ± 0.03 | 5 | |
| P4902D | 0.05 ± 0.01 | <0.0001 | 5 |
| P4902K | 0.09 ± 0.01 | <0.0001 | 5 |
| G4955K | 0.43 ± 0.09 | <0.0001 | 4 |
| G4955L | 0.23 ± 0.05 | 0.0309 | 5 |
| D4956A | 0.38 ± 0.07 | <0.0001 | 4 |
| ANOVA summary: F = 149.7, p < 0.0001 | |||
Data are presented as mean ± SD. The significance of differences in caffeine activation between WT and mutants was evaluated by performing one-way ANOVA with Dunnett's multiple comparisons post hoc testing. A p value < 0.05 was considered statistically significant.